



UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

Office of the Secretary

June 27, 2022

The Bhartiya tv
thebhartiyatv@gmail.com

Re: *In the Matter of Health Research Laboratories, LLC, et al.*, FTC Dkt. No. 9397

Dear Sir or Madam:

Thank you for commenting on the Federal Trade Commission's proposed consent agreement in the above-referenced proceeding. The Commission has considered your comment and placed it on the public record pursuant to Rule 4.9(b)(6)(ii) of the Commission's Rules of Practice, 16 C.F.R. § 4.9(b)(6)(ii).

In your comment, you indicate agreement with the consent agreement and stated "yes we need to focus on health." You do not propose any revisions to the consent agreement. Therefore, after considering your comment, the Commission has determined that the relief set forth in the consent agreement is appropriate and sufficient to remedy the violations alleged in the complaint. Specifically, the proposed Order in the consent agreement prohibits Respondents from selling or advertising any dietary supplements and from making any disease prevention, reduction of risk, cure, mitigation, or treatment advertising claims in the future. The Order also requires that representations about the health benefits, safety, performance or efficacy of any Food or Drug be non-misleading and substantiated by competent and reliable scientific evidence.

At this time, the Commission has determined that the public interest would be served by issuing the Decision and Order in final form without modification. The final Decision and Order and other relevant materials are available on the Commission's website at <http://www.ftc.gov>. It helps the Commission's analysis to hear from a variety of sources in its work, and we thank you again for your comment.

By direction of the Commission.

April J. Tabor
Secretary